Rhenman & Partners Asset Management’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-221,351
| Closed | -$18.8M | – | 96 |
|
|
2020
Q3 | $18.8M | Sell |
221,351
-238,649
| -52% | -$12.1M | 1.67% | 23 |
|
|
2020
Q2 | $16.3M | Sell |
460,000
-130,000
| -22% | -$3.8M | 1.76% | 20 |
|
|
2020
Q1 | $7.95M | Sell |
590,000
-110,000
| -16% | -$1.85M | 1.11% | 41 |
|
|
2019
Q4 | $14.8M | Sell |
700,000
-150,000
| -18% | -$2.65M | 1.62% | 23 |
|
|
2019
Q3 | $11.3M | Sell |
850,000
-1,367
| -0.2% | -$20.1K | 1.41% | 28 |
|
|
2019
Q2 | $11.8M | Buy |
851,367
+235,000
| +38% | +$3.54M | 1.3% | 33 |
|
|
2019
Q1 | $11.8M | Buy |
616,367
+136,037
| +28% | +$2.19M | 1.38% | 27 |
|
|
2018
Q4 | $6.85M | Buy |
480,330
+55,000
| +13% | +$1.09M | 0.78% | 50 |
|
|
2018
Q3 | $8.86M | Sell |
425,330
-30,000
| -7% | -$711K | 0.89% | 50 |
|
|
2018
Q2 | $10.8M | Buy |
455,330
+40,000
| +10% | +$804K | 1.1% | 45 |
|
|
2018
Q1 | $6.07M | Sell |
415,330
-65,000
| -14% | -$1.06M | 0.75% | 50 |
|
|
2017
Q4 | $7.76M | Sell |
480,330
-19,670
| -4% | -$232K | 1.05% | 36 |
|
|
2017
Q3 | $6.99M | Sell |
500,000
-29,610
| -6% | -$295K | 0.89% | 42 |
|
|
2017
Q2 | $4.68M | Buy |
529,610
+50,000
| +10% | +$351K | 0.67% | 56 |
|
|
2017
Q1 | $3.1M | Buy |
+479,610
| New | +$2.43M | 0.49% | 68 |
|
Rhenman & Partners Asset Management's IMMU Position: Q4 2020 in Review
Rhenman & Partners Asset Management sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 221,351 shares — an estimated $18.8M sold.
Rhenman & Partners Asset Management first reported a position in IMMU in Q1 2017 and held it in 15 quarters. The position peaked at $18.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Rhenman & Partners Asset Management reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Rhenman & Partners Asset Management sold 221,351 Immunomedics Inc shares in Q4 2020, an estimated $18.8M.
- Rhenman & Partners Asset Management first reported a position in Immunomedics Inc in Q1 2017 and held it in 15 quarters.
- Rhenman & Partners Asset Management's Immunomedics Inc position peaked at $18.8M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.